Autophagy : Moving Benchside Promises to Patient Bedsides - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Current Cancer Drug Targets Année : 2015

Autophagy : Moving Benchside Promises to Patient Bedsides

Résumé

Survival rates of patients with metastatic or recurrent cancers have remained virtually unchanged during the past 30 years. This fact makes the need for new therapeutic options even more urgent. An attractive option would be to target autophagy, an essential quality control process that degrades toxic aggregates, damaged organelles, and signaling proteins, and acts as a tumor suppressor pathway of tumor initiation. Conversely, other fascinating observations suggest that autophagy supports cancer progression, relapse, metastasis, dormancy and resistance to therapy. This review provides an overview of the contradictory roles that autophagy plays in cancer initiation and progression and discusses the promises and challenges of current strategies that target autophagy for cancer therapy.
Fichier principal
Vignette du fichier
Curr Cancer Drug Targets 2015 Belaid.pdf (1.76 Mo) Télécharger le fichier
Origine Publication financée par une institution

Dates et versions

hal-02411388 , version 1 (24-11-2020)

Identifiants

Citer

Amine Belaïd, Papa Diogop Ndiaye, Harilaos Filippakis, Jérémie Roux, Eric Röttinger, et al.. Autophagy : Moving Benchside Promises to Patient Bedsides. Current Cancer Drug Targets, 2015, 15 (8), pp.684-702. ⟨10.2174/156800961508151001102452⟩. ⟨hal-02411388⟩
30 Consultations
161 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More